---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-043287"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2023-04-10T23:59:59+00:00"
generated_at: "2026-06-17T04:25:01.700923+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Regeneron expects $56M IPR&D charge in Q1 2023 from Sonoma collaboration, ~$0.42 EPS impact

## Summary
- Pre-tax acquired IPR&D charge of ~$56M for Q1 2023 related to Sonoma Biotherapeutics collaboration.
- Expected to reduce both GAAP and non-GAAP diluted EPS by approximately $0.42.
- Charge is preliminary and subject to final financial statement closing procedures.
- Relates to an up-front payment under the previously announced collaboration and license agreement.

## SEC filing metadata
- accession: 0001104659-23-043287
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2023-04-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000110465923043287/0001104659-23-043287-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000110465923043287/tm2312136d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-043287
- JSON: https://secwatch.observer/filing/0001104659-23-043287.json
- Plain text: https://secwatch.observer/filing/0001104659-23-043287.txt

## Key facts
- Earnings Releases
  REGENERON PHARMACEUTICALS, INC. reported preliminary financial results for first quarter 2023.
  - Period: first quarter 2023
  - Result: preliminary results
  source text: Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the first quarter 2023 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $56 million on a pre-tax basis, primarily relating to an up-front payment in connection with the Company’s previously announced collaboration and license agreement with Sonoma Biotherapeutics, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000110465923043287/0001104659-23-043287-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.